Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 5/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.41 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.41 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547124 | 1.00 | ATM (0.60) | ATMTDP1MAPTALDH1A1KDM4E | |
| SCHEMBL102898 | 0.85 | ATM (0.55) | ATMTDP1MAPTALDH1A1KDM4E | |
| SCHEMBL7392802 | 0.84 | TTR (0.56) | ATMTDP1MAPTALDH1A1LMNA | |
| SCHEMBL24137366 | 0.83 | ATM (0.58) | ATMTDP1MAPTALDH1A1CYP3A4 | |
| SCHEMBL16951913 | 0.83 | ATM (0.58) | ATMTDP1MAPTALDH1A1LMNA | |
| SCHEMBL564374 | 0.83 | ATM (0.58) | ATMTDP1MAPTALDH1A1LMNA | |
| SCHEMBL8943778 | 0.82 | HSPB1 (0.54) | ATMTDP1MAPTALDH1A1KDM4E | |
| SCHEMBL3512659 | 0.80 | ATM (0.55) | ATMTDP1MAPTALDH1A1CYP3A4 | |
| SCHEMBL3512661 | 0.80 | ATM (0.55) | ATMTDP1MAPTALDH1A1CYP3A4 | |
| SCHEMBL14269667 | 0.79 | ATM (0.53) | ATMTDP1MAPTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 449 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924337-A | Synthesis method of clenbuterol | 遵义医科大学附属医院 | 2024-04-26 | — | — | CN | claimed |
| CN-107522766-B | Ursolic acid quinolyl hydrazide derivatives with anti-tumor activity and preparation method and application thereof | 南京林业大学 | 2020-03-27 | — | — | CN | claimed |
| EP-2245132-B1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC NO 41424 (GB) | 2017-10-18 | — | — | EP | claimed |
| CN-102015993-B | Encapsulated benefit agent | UNILEVER PLC | 2013-03-27 | — | — | CN | claimed |
| CN-102015993-A | Encapsulated benefit agent | UNILEVER PLC | 2011-04-13 | — | — | CN | claimed |
| EP-2245132-A1 | ENCAPSULATED BENEFIT AGENT | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) | 2010-11-03 | — | — | EP | claimed |
| WO-2009103576-A1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC (GB) | 2009-08-27 | — | — | WO | claimed |
| US-4456772-A | Process for the preparation of optionally substituted fluoro-nitro-benzaldehydes | BAYER AKTIENGESELLSCHAFT (DE) | 1984-06-26 | — | — | US | claimed |
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2025-10-07 | — | — | US | disclosed |
| EP-4594307-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4574822-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | Kamari Pharma Ltd. (IL) | 2025-06-25 | — | — | EP | disclosed |
| US-20250154111-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| EP-0061113-A1 | Method for the preparation of optionally substituted fluoronitrobenzaldehydes | BAYER AG (DE) | 1982-09-29 | — | — | EP | disclosed |
| US-4306900-A | Herbicidal nitrodiphenyl ethers | ROHM AND HAAS COMPANY (US) | 1981-12-22 | — | — | US | disclosed |
| US-4134981-A | ANTIALLERGENS | PFIZER INC. (US) | 1979-01-16 | — | — | US | disclosed |
| US-4120962-A | Fused pyrimidin-4(3H)-ones as antiallergy agents | PFIZER INC. (US) | 1978-10-17 | — | — | US | disclosed |
| US-4044134-A | FUSED WITH QUINOLINE OR PYRIDINE, 2-METHYL, ETHYL, OR ACETYL GROUP | PFIZER INC. (US) | 1977-08-23 | — | — | US | disclosed |
| US-3974161-A | Fused pyrimidin-4(3H)-ones as antiallergy agents | PFIZER INC. (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | ATM 3391/4885TDP1 1639/4885MAPT 3652/4885 |
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | TNNT2, TNNI3, TNNC1 | ATM 2561/4885TDP1 1598/4885MAPT 4455/4885 |
| US-20250154111-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | ATM 2000/4885TDP1 577/4885MAPT 3072/4885 |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | ATM 2000/4885TDP1 577/4885MAPT 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.